glycopeptide

Phleomycin is one of the anticancer glycopeptide antibiotics which cause DNA cleavage. It is similar to Bleomycin which binds and intercalates DNA to damage the integrity of the double helix.

A40926 (Dalbavancin Impurity) is effective against Gram positive bacteria.

GPEP FA2-KVANKT glycopeptide (F(3)A2 glycan-KVANKT & F(6)A2 glycan-KVANKT) is a type of N-glycoprotein that serves as a multifunctional fluorescent linker. The resulting conjugates demonstrate high sensitivity and specificity by simulating the antenna elements of N-glycans.

A2G2S2-KVANKTglycopeptide is a multifunctional fluorescent linker, classified as a polyglycan N-glycoprotein. The resulting conjugates exhibit high sensitivity and specificity by mimicking the antennae components of N-glycans.

Sialylglycopeptide is a useful organic compound for research related to life sciences. The catalog number is T64549 and the CAS number is 189035-43-6.

Dalbavancin (BI-397), a novel second-generation lipoglycopeptide antibiotic, possesses in vitro activity against a variety of Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE),Dalbavancin inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 μg/mL and 0.25 μg/mL, respectively

Bleomycin sulfate is a glycopeptide antibiotic with antitumor activity. It is commonly used as a DNA-damaging agent and DNA synthesis inhibitor. It functions by inducing DNA strand breaks without affecting RNA strands. Bleomycin sulfate is widely used in cancer research and for establishing pulmonary fibrosis animal models.

Bleomycin hydrochloride is a glycopeptide antibiotic and a DNA synthesis inhibitor. Bleomycin Sulfate can cause DNA strand breaks but not RNA strand breaks. Bleomycin Sulfate has anti-tumor activity.

Vancomycin is a glycopeptide antibiotic that exerts its antibacterial activity by inhibiting the second stage of cell wall synthesis in susceptible bacteria. It also alters cell membrane permeability and selectively inhibits RNA synthesis. Vancomycin is commonly used to treat severe infections resistant to other antibiotics and is frequently employed in experimental studies to induce kidney injury models.

SNAP 398299 is a Glycopeptide Receptor Type 3 (Gal3) antagonist with anxiolytic and antidepressant-like effects and is used in the study of mood disorders.

Vancomycin hydrochloride (Vancomycin HCl) is a glycopeptide antibiotic that targets Peptidoglycan in bacterial cell wall synthesis. Vancomycin hydrochloride is mainly used for the treatment of severe Gram-positive bacterial infections.

Teicoplanin (MDL-507) is a semisynthetic glycopeptide antibiotic, used to treat Gram-positive bacteria.

Dirithromycin (LY237216) is a macrolide glycopeptide antibiotic. It is used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.

MAC-545496 is a glycopeptide-resistance-associated protein R (GraR) inhibitor, is an antivirulence agent.

Mideplanin is a glycopeptide antibiotic.

Teicoplanin aglycone is an antibacterial glycopeptide antibiotic used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including Enterococcus faecalis and methicillin-resistant Staphylococcus aureus.

Oritavancin diphosphate (LY333328 diphosphate) is a novel semisynthetic glycopeptide antibiotic developed for treating serious Gram-positive bacterial infections.

Chloroorienticin A is a glycopeptide antibiotic that exerts its antibacterial activity by binding to the D-Ala-D-Ala termini of peptidoglycan precursors, thereby inhibiting bacterial cell wall biosynthesis. It shows strong activity against Gram-positive bacteria, particularly Staphylococcus and Streptococcus species.

Eremomycin is a glycopeptide antibiotic produced by actinomycetes. Structurally similar to vancomycin derivatives, Eremomycin exerts its antibacterial effect by inhibiting peptidoglycan synthesis. Eremomycin exhibits strong activity against a wide range of Gram-positive bacteria and is widely used in research on antibiotic mechanisms and resistance.

Lipid II binder 5107930 is a lipid II binder which causes specific upregulation of the vancomycin-resistance associated gene vraX, which is implicated in the cell wall stress stimulon that confers glycopeptide resistance.

N-Demethylvancomycin is a glycopeptide antibiotic that has been found inNocardia orientalis.1It is active against several strains ofS. aureusandS. epidermidisin vitroandin vivo.2Formulations containing N-demethylvancomycin have been used in the treatment of bacterial infections. 1.Boeck, L.D., Mertz, F.P., Wolter, R.K., et al.N-demethylvancomycin, a novel antibiotic produced by a strain of Nocardia orientalis. Taxonomy and fermentationJ. Antibiot. (Tokyo)37(5)446-453(1984) 2.Hunt, A.H., Marconi, G.G., Elzey, T.K., et al.A51568A: N-demethylvancomycinJ. Antibiot. (Tokyo)37(8)917-919(1984)

Oritavancin is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci.

Ristocetin A, a glycopeptide related to vancomycin, is an antibiotic produced by the microorganism Nocardia lurida[1]. Ristocetin A is currently in clinical use to treat bacterial infections [1]. Ristocetin A is an antibiotic which can be used to treat staphylococcal infections. The side effects of ristocetin A include thrombocytopenia and platelet agglutination. Ristocetin A has been used in two assays: the ristocetin cofactor assay and the ristocetin-induced platelet aggregation assay. These two assays could be used to diagnosis the von Willebrand disease and other bleeding disorders [2, 3]. The structural features of Ristocetin A are similar to vancomycin.

Parvodicin complex is a mixture of closely related lipophilic glycopeptides originally isolated from A. parvosata. The parvodicin complex has activity against Gram-positive bacteria (MICs = 0.8-12.5 μg/ml) including methicillin-resistant strains of S. aureus (MRSA), S. hemolyticus, and E. faecalis (MICs = 0.1-25 μg/ml). Glycopeptide antibiotics act by preventing cell wall synthesis by binding and sequestering a cell wall precursor with a D-alanine-containing peptide.